News from the healthcare data industry
We recently commissioned a review into our usage of real world evidence (RWE) and patient reported outcomes (PROs) in the regulation of medicines and medical devices. This considered stakeholders’ understanding of what RWE and PROs are, and how we and other international regulators use them. We use both RWE and…
Contributed by: Taren Grom, Editor As we strategized how to present this “last magazine” of PharmaVOICE, we wanted to do something a little different. Instead of our annual Year in Preview issue, we asked our community of thought leaders to reflect on the past 20 years and share their perspectives…
CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, today announced a multi-year, strategic collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) in which the two companies will work together to gather insights, discover novel drug targets, and aim to develop therapeutics for the broader oncology community. By combining the capabilities of…
By Stacy Cline Amin, Morrison & Foerster; former chief counsel of the FDA Health policy experts have talked excitedly about the potential for real-world evidence (RWE) to transform healthcare delivery and drug development for years. But the regulatory framework has remained in a state of infancy, despite Congress’s focus on…
As you might guess, health-technology innovations relating to the COVID-19 pandemic are well represented among the winners of Fast Company’s first Next Big Things in Tech awards. But the winners and honorable mentions span a gamut of issues related to medical challenges, including a new device that makes dialysis less of a…
We spoke to four leaders harnessing AI in clinical trials about its challenges and their vision for AI in the future. Artificial Intelligence (AI) is quickly weaving itself into the fabric of our lives across all industries. The life sciences have seen a dramatic leap forward into the digital age…
Tempus is integrating information from the Memorial Sloan Kettering Cancer Center’s OncoKB database and NCCN Guidelines into its clinical reports, providing physicians robust, well-vetted guidelines at their fingertips Tempus, a leader in artificial intelligence and precision medicine, today announced that it will incorporate data from both the Memorial Sloan Kettering…
Tempus expands its existing provider EHR integrations to offer physicians seamless access to its genomic testing Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamless access…
November 18, 2021 10:46 AM Eastern Standard Time CHICAGO–(BUSINESS WIRE)–Tempus, a leader in artificial intelligence and precision medicine, announced that it is working with Epic to offer providers in-workflow integrations at scale. Since its founding, Tempus has strived to provide physicians seamless access to next-generation sequencing and the accompanying data…
Komodo’s real-world evidence deepens industry understanding of racial disparities to close gaps in care, advance diversity in clinical trials San Francisco – November 18, 2021: Komodo Health today announced the expansion of its Healthcare Map™, adding new demographic characteristics to help its customers advance health equity and close gaps in care through…